Human B Cells Expression in Terminally Differentiating Induces
Total Page:16
File Type:pdf, Size:1020Kb
1,25-Dihydroxyvitamin D3 Induces CCR10 Expression in Terminally Differentiating Human B Cells This information is current as Aiko-Konno Shirakawa, Daisuke Nagakubo, Kunio of September 28, 2021. Hieshima, Takashi Nakayama, Zhe Jin and Osamu Yoshie J Immunol 2008; 180:2786-2795; ; doi: 10.4049/jimmunol.180.5.2786 http://www.jimmunol.org/content/180/5/2786 Downloaded from References This article cites 55 articles, 29 of which you can access for free at: http://www.jimmunol.org/content/180/5/2786.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology 1,25-Dihydroxyvitamin D3 Induces CCR10 Expression in Terminally Differentiating Human B Cells1 Aiko-Konno Shirakawa,2 Daisuke Nagakubo,2 Kunio Hieshima, Takashi Nakayama, Zhe Jin, and Osamu Yoshie3 In the B cell lineage, CCR10 is known to be selectively expressed by plasma cells, especially those secreting IgA. In this study, we examined the regulation of CCR10 expression in terminally differentiating human B cells. As reported previously, IL-21 efficiently induced the differentiation of activated human CD19؉ B cells into IgD؊CD38؉ plasma cells in vitro. A minor proportion of the ؉ ؊ ؉ resulting CD19 IgD CD38 cells expressed CCR10 at low levels. 1,25-Dihydroxyvitamin D3 (1,25-(OH)2D3), the active metabolite ؉ ؊ ؉ of vitamine D3, dramatically increased the proportion of CD19 IgD CD38 cells expressing high levels of CCR10. The 1,25- ؉ ؉ (OH)2D3 also increased the number of CCR10 cells expressing surface IgA, although the majority of CCR10 cells remained Downloaded from negative for surface IgA. Thus, 1,25-(OH)2D3 alone may not be sufficient for the induction of IgA expression in terminally differentiating human B cells. To further determine whether 1,25-(OH)2D3 directly induces CCR10 expression in terminally differentiating B cells, we next performed the analysis on the human CCR10 promoter. We identified a proximal Ets-1 site and an upstream potential vitamin D response element to be critical for the inducible expression of CCR10 by 1,25-(OH)2D3.We confirmed the specific binding of Ets-1 and 1,25-(OH)2D3-activated vitamin D receptor to the respective sites. In conclusion, 1,25-(OH)2D3 efficiently induces CCR10 expression in terminally differentiating human B cells in vitro. Furthermore, the human http://www.jimmunol.org/ CCR10 promoter is cooperatively activated by Ets-1 and vitamin D receptor in the presence of 1,25-(OH)2D3. The Journal of Immunology, 2008, 180: 2786–2795. lasma cells represent the terminal stage of B cell differ- gration and tissue localization of lymphocytic cells (2, 4). As for entiation and secrete large amounts of Ab. The transcrip- plasma cells, CXCR4 has been demonstrated to guide the move- P tion factors Blimp-1 and XBP-1 play essential roles in the ment of plasma cells to splenic red pulp, lymph node medullary plasma cell differentiation and function (1). Plasma cells exhibit cords, and bone marrow, where its ligand CXCL12 is abundantly preferential tissue localization in accordance with the route of im- produced (5). CXCR3 mobilizes IgG-secreting plasma cells to in- munization and the isotypes of Ig secreted. IgG-secreting plasma flammatory sites, where its ligands CXCL9, CXCL10, and/or by guest on September 28, 2021 cells are mainly induced by a systemic route of immunization and CXCL11 are strongly up-regulated (6–8). CCR9 contributes to the preferentially localize in the bone marrow. In contrast, IgA-secret- localization of IgA-secreting plasma cells to the small intestine ing plasma cells are predominantly induced by a mucosal route of (9–11), where its ligand CCL25 is selectively produced by the immunization and preferentially localize in the mucosal tissues (2). intestinal epithelial cells (11–13). Differential expression of tissue-specific adhesion molecules has CCR10 was originally identified as the receptor for CCL27 (14), 4 been demonstrated in Ab-secreting cells (ASCs) depending on the which is selectively expressed by epidermal keratinocytes (15, 16). route of immunization (3). Recently, chemokines and their recep- Accordingly, CCR10 has been shown to be expressed by skin- tors have been attracting much attention as the regulators of mi- homing effector/memory T cells expressing cutaneous lymphocyte Ag (14, 17, 18). Subsequently, another ligand of CCR10 was iden- tified and termed CCL28, which is widely expressed by the Department of Microbiology, Kinki University School of Medicine, Osaka-Sayama, epithelial cells of various mucosal tissues (11, 19–21). Thus, cer- Osaka, Japan tain types of CCR10-expressing cells must be present in the mu- Received for publication November 29, 2006. Accepted for publication December 13, 2007. cosal tissues. Previously, we have demonstrated that EBV-immor- talized human B cells express CCR10, although CCR10 is not The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance inducible by EBV-encoded latent genes (22). This was rather un- with 18 U.S.C. Section 1734 solely to indicate this fact. expected because the expression of CCR10 had not been described 1 This work was supported by a grant-in-aid from the Ministry of Education, Culture, at any of the developmental or differentiation stages of B cells Sports and Technology, Japan; by Solution-Oriented Research for Science and Tech- nology from the Japan Science and Technology Corporation; and by the High-Tech examined to date (23). Because EBV-immortalized B cells resem- Research Center Project for Private Universities: matching fund subsidy from the ble plasma cells in terms of the continuous production of Igs (24), Ministry of Education, Culture, Sports, Science and Technology of Japan, 2002–2009. we hypothesized that CCR10 might be selectively expressed at the 2 A.-K.S. and D.N. contributed equally to this work. terminal differentiation stage of B cells. We have indeed demon- 3 Address correspondence and reprint requests to Dr. Osamu Yoshie, Department of strated that a substantial fraction of plasma cells derived from hu- Microbiology, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka- Sayama, Osaka 589-8511, Japan. E-mail address: [email protected] man bone marrow expresses CCR10 and efficiently migrates to its 4 ligands CCL27 and CCL28 (25). Furthermore, Butcher and his Abbreviations used in this paper: ASC, Ab-secreting cell; 1,25-(OH)2D3, 1,25-di- hydroxyvitamin D3; DC, dendritic cell; GALT, gut-associated lymphoid tissue; HEK, colleagues (26, 27) have demonstrated that IgA-ASCs present in human embryonic kidney; LCL, lymphoblastoid cell line; RA, all-trans retinoic acid; various mucosal tissues commonly express CCR10. We have also VDR, vitamin D receptor; VDRE, vitamin D response element. demonstrated that CCR10 plays an important role in the homing of Copyright © 2008 by The American Association of Immunologists, Inc. 0022-1767/08/$2.00 IgA-ASCs into the small intestine and colon (11). Consequently, it www.jimmunol.org The Journal of Immunology 2787 is now considered that the CCL28-CCR10 system comprises an Systems and Jackson ImmunoResearch Laboratories, respectively. The important element in the common mucosal immune system by pro- 1,25-(OH)2D3 was purchased from Cayman Chemical. All-trans retinoic acid (RA) was purchased from Sigma-Aldrich. 22-Oxa-1,25-(OH) D moting the wide distribution of locally induced IgA-ASCs to var- 2 3 (OCT), an analog of 1,25-(OH)2D3 and a VDR agonist, was provided by ious mucosal tissues in the body (2). However, the regulatory Chugai Pharmaceutical. TEI-9647, a VDR antagonist, was provided by mechanism of CCR10 expression in terminally differentiating B Teijin Institute for Bio-Medical Research. Unused transfusion blood sam- cells has not been determined yet. ples were provided by Osaka Red Cross Hospital. The use of the blood The 1,25-dihydroxyvitamin D (1,25-(OH) D ) is the biologi- samples was approved by the ethical committee of Kinki University School 3 2 3 of Medicine. PBMC were prepared using Ficoll-Paque. CD19ϩ B cells cally active metabolite of vitamin D3, which binds and activates were purified from PBMC by negative selection using BD IMag Human B the nuclear vitamin D receptor (VDR). The activated VDR dimer- Lymphocyte Enrichment Set-DM and BD IMagnet (BD Biosciences). The izes with another nuclear receptor, one of the retinoid X receptors, preparations were typically Ͼ90% CD19ϩ B cells. Induction of B cell and the heterodimer binds with high affinity to vitamin D response differentiation into plasma cells was performed essentially as described previously (36). Briefly, purified CD19ϩ B cells were cultured in the pres- elements (VDREs) in the promoter region of target genes (28). Ј ence of anti-IgM F(ab )2 at 5 g/ml, anti-CD40 at 1 g/ml, and IL-21 at Besides the role in calcium homeostasis, 1,25-(OH)2D3 is also 100 ng/ml for 6 days. On day 3, 1,25-(OH)2D3, OCT, TEI-9647, and RA known to exert potent immunomodulatory activities (29–31).